AngelMD
VC Fund
Denver, United States
AngelMD is a VC fund in Denver focused on Health Care and Biotechnology. AngelMD connects the largest pipeline of medical startups in the world with physicians and dentists who help evaluate and advise the companies. Through a systematic and scientific pre-investment analysis process and post investment support from the clinician network, the company de-risks the investment opportunities for investors (family offices,funds, corporate investors) in early stage healthcare.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries AngelMD invests in
Stages AngelMD invests in
Countries AngelMD invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jens Francis
|
|||
|
Shamir Patel
|
|||
Tobin Arthur
|
|||
2 more contacts available
Investment Focus
Industry
- Health Care 10 (67%)
- Biotechnology 9 (60%)
- Medical 6 (40%)
- Therapeutics 6 (40%)
- Medical Device 5 (33%)
Stage
- Seed 4 (27%)
- Funding Round 4 (27%)
- Series A 2 (13%)
- Series B 2 (13%)
- Angel 1 (7%)
Country
- United States 12 (80%)
- Canada 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jens Francis
Founder Emeritus
|
Founder Emeritus | Total investments: 0 | Find email | |
|
Shamir Patel
General partner
|
General partner | Total investments: 1 | Find email | |
|
Tobin Arthur
Executive Chairman
|
Executive Chairman | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OraQ AI
|
OraQ AI is a clinical decision support system that empowers patients to improve wellness practice through a holistic approach. OraQ AI was founded in 2021 and was headquartered in Alberta, Canada. | $1.8M / Seed / Nov 25, 2024 | |
Raydiant Oximetry
|
Raydiant Oximetry is a medical device company focused on improving outcomes for mothers and babies during childbirth. The company develops a low-cost, non-invasive biomedical device to monitor the oxygen levels in fetal blood. It develops and distributes a non-invasive technology that directly monitors a babies' oxygenation during pregnancy.This technology will lead to better patient care and greatly reduce the number of unnecessary cesarean sections.Founded in 2015 by Neil Ray, Raydiant Oximetry is headquartered in Mountain View, California. | $5.6M / Series A / Feb 01, 2019 | |
Neumentum
|
Neumentum neurology specialty pharmaceutical company that develops and commercializes novel non-opioid pain products. At Neumentum, we are dedicated to developing safe, effective treatment options that address unmet needs in the management of pain, without the potential risks of misuse, addiction, or life-threatening side effects that may be foundwith opioid products.Neumentum has global rights to five novel non-opioid pain products, the most advanced of which are two phase 3-ready injectable products under development for acute postsurgical pain. | Sep 21, 2018 | |
Access Vascular
|
Access Vascular has developed a disruptive technology using a novel material process intended to significantly reduce the blood component accumulation (thrombosis or blood clotting) that leads to occlusions and infections. Over the last three years, Access Vascular’s technology has demonstrated the potential for superior clinical outcomes and lowerhealthcare costs compared with existing technologies. For patients, their solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment, and minimize pain.Their technology has the potential to address a range of clinical needs in a variety of indications. Access Vascular is focused initially on launching their HydroPICC, a peripherally inserted central catheter with superior material performance over the current lagging technology. | $3.4M / Aug 23, 2018 | |
|
Raydiant Oximetry
|
Raydiant Oximetry is a medical device company focused on improving outcomes for mothers and babies during childbirth. The company develops a low-cost, non-invasive biomedical device to monitor the oxygen levels in fetal blood. It develops and distributes a non-invasive technology that directly monitors a babies' oxygenation during pregnancy.This technology will lead to better patient care and greatly reduce the number of unnecessary cesarean sections.Founded in 2015 by Neil Ray, Raydiant Oximetry is headquartered in Mountain View, California. | $1M / Seed / Jul 30, 2018 | |
Iterion Therapeutics
|
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivintdemonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.It was founded in 2010 and is headquartered in Houston, Texas. | $2.6M / Series B / Jun 27, 2018 | |
Lifesprout
|
LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. They offer revolutionary products for aesthetic and regenerative medicine. They have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions ofpatients each year with soft tissue losses from aging, cancer, and metabolic disease. | $6.5M / Seed / Jun 18, 2018 | |
Sensulin
|
Sensulin, LLC is developing a true once-a-day glucose-responsive insulin, that may mimic a healthy human pancreas. Sensulin may eliminate the need for basal & prandial insulin, offer a substantial improvement in the standard of care, and most importantly, give those with diabetes a chance at a normal life. | Series B / May 23, 2018 | |
Fibralign Corporation
|
Fibralign Corporation utilizes Nanoweave® a proprietary scaffolding technology to develop advanced biomedical devices.Fibralign has launched its first product, the BioBridge® Collagen Matrix, and is now engaging in clinical studies to evaluate its use for treating and preventing secondary lymphedema, as well as advancing R&D development fornew applications for treating ischemia and novel delivery devices for use with stem cells and gene therapy. | Nov 27, 2017 | |
|
Access Vascular
|
Access Vascular has developed a disruptive technology using a novel material process intended to significantly reduce the blood component accumulation (thrombosis or blood clotting) that leads to occlusions and infections. Over the last three years, Access Vascular’s technology has demonstrated the potential for superior clinical outcomes and lowerhealthcare costs compared with existing technologies. For patients, their solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment, and minimize pain.Their technology has the potential to address a range of clinical needs in a variety of indications. Access Vascular is focused initially on launching their HydroPICC, a peripherally inserted central catheter with superior material performance over the current lagging technology. | $3.8M / Aug 28, 2017 | |
| See all 15 investments → | |||
Co-Investors
Avestria Ventures
1 deal together
Cancer Prevention and Research Institute of Texas
1 deal together
Center of Aging and Brain Health Innovation
1 deal together
GOOSE Capital
1 deal together
Health Wildcatters
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does AngelMD invest in?
AngelMD invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Funding Round stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact AngelMD?
Public channels for AngelMD include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AngelMD?
The team at AngelMD includes Jens Francis (Founder Emeritus), Shamir Patel (General partner) and Tobin Arthur (Executive Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
